MedTrace Logo

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals

NCT04340349 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2021-06-29

No results posted yet for this study

Summary

This study will investigate the security and efficacy of a daily low dose of hydroxychloroquine and Bromhexine, in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health In Mexico City.

Conditions

  • Hydroxychloroquine
  • Antimalarials
  • Enzyme Inhibitors
  • Antirheumatic Agents

Interventions

DRUG

Hydroxychloroquine Sulfate

A daily low dose of Hydroxychloroquine Sulfate. Increase the endosomal pH and inhibits of ACE2 glycosylation receptor.

DRUG

Bromhexine 8 MG

TMPRSS2 blocker

Sponsors & Collaborators

  • Instituto Nacional de Rehabilitacion

    lead OTHER_GOV

Principal Investigators

  • Julio Granados-Montiel, MD, PhD · Instituto Nacional de Rehabilitacion

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-05-30
Completion
2021-06-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04340349 on ClinicalTrials.gov